XOMA Corporation Stock price

Equities

XOMA

US98419J2069

Biotechnology & Medical Research

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
24.05 USD +3.04% Intraday chart for XOMA Corporation -1.96% +30.00%
Sales 2024 * 14.1M Sales 2025 * 20.65M Capitalization 280M
Net income 2024 * -24M Net income 2025 * -20M EV / Sales 2024 * 19.8 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 13.5 x
P/E ratio 2024 *
-11.2 x
P/E ratio 2025 *
-14.1 x
Employees 13
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.04%
1 week-1.96%
Current month-1.07%
1 month-3.61%
3 months+26.98%
6 months+68.89%
Current year+30.00%
More quotes
1 week
23.00
Extreme 23
25.95
1 month
23.00
Extreme 23
26.83
Current year
18.57
Extreme 18.5701
26.83
1 year
13.48
Extreme 13.48
26.83
3 years
13.48
Extreme 13.48
41.88
5 years
11.58
Extreme 11.58
46.32
10 years
3.96
Extreme 3.96
119.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 22-12-31
Director of Finance/CFO 50 06-08-13
Chief Investment Officer 43 23-01-02
Members of the board TitleAgeSince
Director/Board Member 58 21-08-05
Chairman 68 10-08-25
Director/Board Member 71 12-12-11
More insiders
Date Price Change Volume
24-03-28 24.05 +3.04% 19,834
24-03-27 23.34 +0.82% 7,215
24-03-26 23.15 -3.54% 7,793
24-03-25 24 -3.23% 16,760
24-03-22 24.8 +1.10% 39,214

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
24.05 USD
Average target price
74 USD
Spread / Average Target
+207.69%
Consensus
  1. Stock
  2. Equities
  3. Stock XOMA Corporation - Nasdaq